ileal neuroendocrine tumor G1

Summary

ileal neuroendocrine tumor G1 (MONDO:0006250) is a cancer and 3 clinical trials. Top therapeutic interventions include paltusotine. A subtype of small intestinal neuroendocrine tumor G1 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ileal neuroendocrine tumor G1
Mondo ID	MONDO:0006250
EFO	EFO:1000300
NCIT	C4935
SNOMED CT	425318003
UMLS	C0745216
MedGen	155426
GARD	0024347
Anatomy (UBERON)	UBERON:0002116
Is cancer (heuristic)	yes

Also known as: carcinoid tumor of ileum · carcinoid tumor of the ileum · carcinoid tumour of ileum · carcinoid tumour of the ileum · grade 1 neuroendocrine neoplasm of ileum · ileal carcinoid tumor · ileal carcinoid tumour · ileal NET G1 · ileal neuroendocrine tumor G1 · ileum carcinoid tumor · ileum carcinoid tumor (disease) · ileum carcinoid tumour · ileum carcinoid tumour (disease) · ileum NET G1 · ileum neuroendocrine neoplasm G1 · ileum neuroendocrine tumor, well differentiated, low grade

Disease family

This is a subtype of small intestinal neuroendocrine tumor G1. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › small intestine neuroendocrine tumor, well differentiated, low or intermediate grade › small intestinal neuroendocrine tumor G1 › ileal neuroendocrine tumor G1

Related subtypes (1): jejunal neuroendocrine tumor G1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07087054	PHASE3	RECRUITING	Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT05361668	PHASE2	COMPLETED	Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
NCT04907643	Not specified	RECRUITING	Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PALTUSOTINE	3	2